sirnaomics
Transcribing For Better Lives

Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

INSIDE INFORMATION
ISSUE OF A WRIT OF SUMMONS

This announcement is made by Sirnaomics Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated December 29, 2022, January 12, 2023, July 8, 2024, December 13, 2024, January 14, 2025, March 18, 2025 and October 31, 2025 (collectively, "**Announcements**"). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company and potential investors that on August 14, 2026, the Company and its direct wholly-owned subsidiary, Sirnaomics (Hong Kong) Limited (collectively, the "**Plaintiffs**") have filed a Writ of Summons (case number: HCA 1427/2026) with the High Court of the Hong Kong Special Administrative Region (the "**Court**") against certain former management of the Group, including Dr. Lu Yang, Dr. Xiaochang Dai and Mr. Yip Wing Kei (collectively, the "**Defendants**").

The claims arise in connection with the Group's investment in the aggregate principal amount of approximately US$20 million in a segregated portfolio of TradArt Flagship Investment SPC (the "**Investment**") as disclosed in the Announcements.

The Plaintiffs claim against the Defendants for, among other things:

(1) breaches of fiduciary duties and/or other duties owed to the Plaintiffs in connection with the Investment (including, without limitation, the decision to make, the monitoring of, and/or the handling of the Investment);

(2) procurement of or involvement in payments, subscriptions or related arrangements without proper authorisation, consent and/or due process; and

(3) damages, equitable compensation, interest, costs and such further and/or other relief as the Court thinks fit.

The Company has instructed its legal advisers to take all necessary steps to uphold the Group's legitimate rights and interests. The Company expressly reserves its rights to take further actions against any other former management, officers or third parties if and when necessary.

The Company will continue to seek legal advice on this matter and will make further announcements as and when appropriate pursuant to the Listing Rules to keep the shareholders and potential investors of the Company informed of any material developments.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.
Poon Hung Fai
Chairman and Executive Director

Hong Kong, August 14, 2026

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Dr. Yin Huijun as non-executive Director, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.